SCHEMBL1890692

SCHEMBL1890692

Cc1cccc2cc(C(C)c3nc(N)nc(N)n3)c(-c3cnn(C)c3)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
MET P08581 1/20 0.35
ATM Q13315 1/20 0.34
AXL P30530 2/20 0.34
PIK3CD O00329 4/20 0.33
PIK3R2 O00459 3/20 0.33
PIK3CA P42336 3/20 0.33
PIK3CG P48736 3/20 0.33
ADORA2A P29274 1/20 0.33
TTK P33981 2/20 0.32
MPO P05164 1/20 0.32
PFKFB3 Q16875 1/20 0.32
ALOX5AP P20292 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
IRAK1 P51617 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
LRRK2 Q5S007 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883325 0.83 ATM (0.42) ATMPIK3CDPIK3CGADORA2A
SCHEMBL1875421 0.81 CYP2A6 (0.40) ATMAXLPIK3CDADORA2A
SCHEMBL1882072 0.80 PIK3CD (0.39) FGFR1FGFR2FGFR3METATM
SCHEMBL14768204 0.80 PFKFB3 (0.39) PIK3CDPIK3R2PIK3CAPIK3CGTTK
SCHEMBL1882069 0.80 PIK3CD (0.39) FGFR1FGFR2FGFR3METATM
SCHEMBL1881117 0.78 ATM (0.48) ATMPIK3CDADORA2A
SCHEMBL1881740 0.78 ADORA2A (0.36) ATMPIK3CDADORA2A
SCHEMBL17530798 0.73 L3MBTL1 (0.52) PIK3CD
SCHEMBL1884684 0.73 BRD4 (0.36) ATMPIK3CD
SCHEMBL1883842 0.71 MEN1 (0.41) FGFR1FGFR2FGFR3ATMPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231641-B1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-06-01 EP disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE FGFR1 3795/4885FGFR2 4576/4885FGFR3 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.